<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cetuximab, a chimeric IgG1 monoclonal antibody against the epidermal growth factor receptor, is indicated for the treatment of epidermal growth factor receptor-expressing <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> and recurrent or metastatic <z:e sem="disease" ids="C0007137,C0751688" disease_type="Neoplastic Process" abbrv="">squamous cell cancer</z:e> of the head and neck after failure of <z:chebi fb="240" ids="33364,33400">platinum</z:chebi>-based therapy </plain></SENT>
<SENT sid="1" pm="."><plain>The commonly reported side effects of cetuximab are infusion-related reactions, <z:hpo ids='HP_0000988'>skin rash</z:hpo>, <z:mp ids='MP_0002899'>fatigue</z:mp>, malaise and <z:hpo ids='HP_0002018'>nausea</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We report a case of aseptic <z:hpo ids='HP_0001287'>meningitis</z:hpo> developing as a rare side effect in a patient of stage <z:mp ids='MP_0010560'>IVB</z:mp> squamous maxillary <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> treated with cetuximab </plain></SENT>
<SENT sid="3" pm="."><plain>To our knowledge, there have been very few cases of cetuximab-induced aseptic <z:hpo ids='HP_0001287'>meningitis</z:hpo> reported in literature </plain></SENT>
<SENT sid="4" pm="."><plain>Clinicians should recognize that self-limiting aseptic <z:hpo ids='HP_0001287'>meningitis</z:hpo> can occur with administration of cetuximab </plain></SENT>
<SENT sid="5" pm="."><plain>Our case report may serve as an additional reference for clinicians encountered with aseptic <z:hpo ids='HP_0001287'>meningitis</z:hpo> in the setting of using cetuximab </plain></SENT>
</text></document>